Protective effects of carvedilol against anthracycline-induced cardiomyopathy. - Wikidata - wikimedia - TriplyDB

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

http://www.wikidata.org/entity/Q42505379

about

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy Cardioprotective interventions for cancer patients receiving anthracyclines Cardioprotective interventions for cancer patients receiving anthracyclines Doxorubicin cardiomyopathy Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms Cardiac effects of anticancer therapy in the elderly Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors Evaluation and management of patients with heart disease and cancer: cardio-oncology Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs Twenty years of anti-HER2 therapy-associated cardiotoxicity Cardiac risk in the treatment of breast cancer: assessment and management.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.Management of chemotherapy induced cardiomyopathy.Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent tr Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?Chemotherapy-induced cardiotoxicity.Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab Anthracycline cardiotoxicity: from bench to bedside.Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Cardiovascular toxicities from systemic breast cancer therapy.Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat.Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy.A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats.

P2860

Q21284978-3671C9B0-0CAE-40B0-AE46-0D52FCB0C57E Q24236338-8FD39714-C12B-4790-887A-7AA67FB68094 Q24243021-AE64CC7D-433F-435D-AECD-C1BD901B9C9F Q24606920-751E337E-0526-4E84-A711-9F948D117BBB Q26742059-619C0CE5-A2DE-4297-8AC4-559766122F72 Q26768272-67296BF3-E5ED-4EAE-974E-B946001DE6B3 Q26795624-AA8B5C41-BCA5-404F-A631-D7D15D59B15F Q26863244-F21294FB-3670-442D-969C-408699F32913 Q26864094-DE702E96-F580-4186-BC86-EB2ADC27E351 Q26865766-59D5E91E-DD40-422B-B948-72763A32AE94 Q26998273-1A9EE84D-CED3-488C-ABDC-4401EBFA1696 Q27007849-2A756B75-2E25-40A3-95FD-B1E265288EDC Q27027354-DABAA40A-25A5-46C8-8A2E-DA7691FB3092 Q28068290-1C44C780-7BB8-4378-841A-8EAB501050FD Q28070311-8EB34F85-EBC1-48E3-A8DE-6553148F7F47 Q28079391-CA0293FE-CA84-44C8-88A9-F0522E8583D7 Q28081385-DAC7EE91-D991-4EC6-9FFB-F7E7F16F2DB2 Q28087776-090E13A7-773E-4E28-AAFE-58C19584EF93 Q30399577-17ACE769-689D-4B4B-819C-4E81D971BF82 Q30401812-20AF79E9-FFDC-40DA-9448-794CDF6A0C93 Q30426853-CE4B865B-EA20-457C-83D1-C2A0552AB9F1 Q30427656-F5C9E905-2002-495E-8F0F-AB12A917BD25 Q30439608-87BB8850-FC53-4DAE-BF74-BA6E0EB407D2 Q30461441-34C4D528-72A2-4A42-8993-8EEB4107AC93 Q33574045-03650278-5CB2-4256-B443-DCC080D72E7A Q33619867-B8AB1DBD-1B3B-4D49-A4F6-097696B73837 Q33807542-017AAA04-1E95-475E-A9A8-66250ECD3E50 Q33973013-32E493F3-5FF4-4373-889F-4ACC4700A044 Q33988329-2118EC66-8B43-4904-9D8A-B54010C8D8A5 Q34258080-440F4F02-79DC-4D67-87BA-A5666B4161D0 Q34474264-181D5347-5167-48A3-9029-A946339CA959 Q34477415-169B2C25-68DA-42A0-8284-2B5ECE832515 Q34626238-B663B398-2D4F-4D79-9868-2C2FC11F7C8E Q34630349-1C756B3C-3872-428D-BC29-3B9F341A6B14 Q34639876-0E94F621-B320-4FA5-A645-D325681D5115 Q34749618-653F83FE-347B-405F-9195-7333B93A7C6F Q34760735-5D9D344D-6271-41B5-9E12-B51110376DC9 Q35024342-E3587BDC-A8C2-4BC2-AA77-340684354CD3 Q35391254-502FEE7A-0799-40D7-921A-5BBF5D1E15AE Q35553674-039118C4-30EF-4EA0-9D9E-5F2A50F63EAD

P2860

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

http://www.wikidata.org/entity/Q42505379

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

@en

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

@nl

type

label

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

@en

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

@nl

prefLabel

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

@en

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

@nl

P1433

Q42505379-99D0E845-FBC6-4B03-BBE0-59D46E06EEC4

P1476

Q42505379-3E804C53-81EF-4BB4-B1D3-6578997577AA

P2093

Q42505379-0B769CD3-0BB7-4153-8155-0D9A98F083EC

Q42505379-1290AC18-D0C4-4821-8140-5050FBB46B53

Q42505379-1FB704F5-0E69-44B2-BA12-29DD66ED809F

Q42505379-2C53B940-EE2B-4204-992D-63DACF7416EB

Q42505379-7006A6ED-CE57-427A-BB23-FD14CE7C9E51

Q42505379-81BBBCEA-1D31-48F7-ADC5-77FABE19CBE0

Q42505379-838486B6-5B7D-4D43-8CCE-254F50EC4171

Q42505379-88422739-B28E-4EC0-96BE-493003A2BF86

Q42505379-DF9FAB8F-2C79-4638-8F4C-81873B9047C3

Q42505379-E77E44A6-0096-4331-8A25-ED54E42E53CA

P304

Q42505379-484A9B29-BC36-4EAA-B9BB-E98FBEF9C660

P31

Q42505379-044D17CE-CE6D-4AAD-BE44-61EB9C2C6DC7

P356

Q42505379-5136004B-4CBB-4977-82E5-948A5BC31E15

P407

Q42505379-94D4752A-5374-46C8-8C7A-09E11F4E1C13

P433

Q42505379-F69438DD-3C1B-4958-9681-0198CAE9FF5E

P478

Q42505379-78EBA912-55DE-4114-885C-603802A03A94

P577

Q42505379-7FA2D257-4276-407F-BB07-DC7AF967569C

P5875

Q42505379-D911EF07-753F-4ABB-823A-818E452F2BC8

P698

Q42505379-D60951CF-959A-4553-93E8-9451E5C4B65C

P356

J.JACC.2006.07.052

P1433

Journal of the American College of Cardiology

P1476

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

@en

P2093

Abdurrahman Oguzhan

http://www.w3.org/2001/XMLSchema#string

Ali Dogan

http://www.w3.org/2001/XMLSchema#string

Ali Ergin

http://www.w3.org/2001/XMLSchema#string

Emrullah Basar

http://www.w3.org/2001/XMLSchema#string

Ibrahim Ozdogru

http://www.w3.org/2001/XMLSchema#string

Namik Kemal Eryol

http://www.w3.org/2001/XMLSchema#string

Nihat Kalay

http://www.w3.org/2001/XMLSchema#string

Ozlem Er

http://www.w3.org/2001/XMLSchema#string

Ramazan Topsakal

http://www.w3.org/2001/XMLSchema#string

Tugrul Inanc

http://www.w3.org/2001/XMLSchema#string

P304

2258-2262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2006.07.052

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6638973

http://www.w3.org/2001/XMLSchema#string

P698

17161256

http://www.w3.org/2001/XMLSchema#string